Abstral Approved in Japan

Recipharm to manufacture, package sublingual opioid for Kyowa Hakko Kirin

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kyowa Hakko Kirin Co. Ltd.‘s Abstral sublingual tablet has been approved for manufacturing and marketing by Japan’s Ministry of Health, Labour and Welfare(MHLW). The approval allows contract manufacturer Recipharm to carry out commercial scale manufacturing and packaging of Abstral for supply to the Japanese market through Kyowa Hakko Kirin. Abstral is a novel, highly potent, rapid disintegration, sublingual formulation of fentanyl citrate. This well-established opioid is used exten...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters